Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNC | P24863 | 1/20 | 0.49 |
| ▸ | CDK8 | P49336 | 1/20 | 0.49 |
| ▸ | MAP3K7 | O43318 | 16/20 | 0.48 |
| ▸ | TAB1 | Q15750 | 16/20 | 0.48 |
| ▸ | MET | P08581 | 1/20 | 0.47 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL658408 | 0.86 | MAP3K7 (0.49) | CCNCCDK8MAP3K7TAB1TNK2 | |
| SCHEMBL658413 | 0.85 | MAP3K7 (0.55) | MAP3K7TAB1TNK2 | |
| SCHEMBL659878 | 0.84 | MAP3K7 (0.61) | MAP3K7TAB1 | |
| SCHEMBL30796549 | 0.79 | CCNC (0.51) | CCNCCDK8MAP3K7TAB1MET | |
| SCHEMBL22777072 | 0.79 | CCNC (0.51) | CCNCCDK8MAP3K7TAB1MET | |
| SCHEMBL2747908 | 0.78 | TNK2 (0.50) | CCNCCDK8MAP3K7TAB1MET | |
| SCHEMBL15416477 | 0.76 | DDB1 (0.53) | CCNCCDK8METTNK2 | |
| SCHEMBL3410098 | 0.76 | MET (0.64) | MET | |
| SCHEMBL660615 | 0.75 | MAP3K7 (0.70) | MAP3K7TAB1 | |
| SCHEMBL2421687 | 0.75 | MET (0.75) | MET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8378104-B2 | 7-aminofuropyridine derivatives | OSI Pharmaceuticals, LLC (US) | 2013-02-19 | — | — | US | disclosed |
| US-20120046267-A1 | 7-AMINOFUROPYRIDINE DERIVATIVES | OSI PHARMACEUTICALS, INC. | 2012-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120046267-A1 | 7-AMINOFUROPYRIDINE DERIVATIVES | MAP3K5, STK17A, MAPKAPK5 | CCNC 1774/4885CDK8 401/4885MAP3K7 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.